Genmab Leverages ChatGPT Enterprise by OpenAI for AI-Driven Innovation in Biotech

Genmab, a global leader in biotechnology, has always been at the forefront of innovation. Specializing in pioneering next-generation antibody therapies for treating cancer and other serious diseases, Genmab has now taken a bold step forward by integrating AI into every aspect of its operations. The company’s recent initiative, AI Everywhere, is designed to bring the benefits of AI to its over 2,000 employees. By partnering with OpenAI and embracing ChatGPT Enterprise, Genmab has positioned itself as a trailblazer in utilizing AI to accelerate scientific research, streamline workflows, and transform patient care.

Genmab’s Mission: Transforming Patient Care with AI

At the core of Genmab’s mission is the development of “knock-your-socks-off” (KYSO®) antibody treatments. These therapies aim to revolutionize patient care by providing groundbreaking solutions for serious diseases like cancer. As part of this vision, Genmab has embraced AI as a critical tool in its arsenal, leveraging it to improve the quality of their science, enhance decision-making, and optimize the efficiency of bringing life-saving medicines to patients.

Tahi Ahmadi, Executive Vice President and Chief Medical Officer at Genmab, remarked, “Our ambition is to integrate AI into everything we do. We anticipated AI to contribute significantly to the quality of our science, decision making, and efficiency in bringing medicines to patients.”

Adopting ChatGPT Enterprise Across Operations

Genmab’s growth has been rapid, with the company tripling in size in recent years. This expansion created operational challenges and a need for new ways to manage vast amounts of complex scientific data. To address these challenges, Genmab launched ChatGPT Enterprise, rolling it out to 1,000 employees just one month after the product’s release. Today, less than a year later, over 2,000 licenses have been issued as part of the company’s AI Everywhere initiative.

This widespread adoption has provided employees with a transformative tool to assist with various tasks. To help employees maximize the value of ChatGPT, Genmab implemented a simple strategy: workers were encouraged to give ChatGPT their job description and ask, "What can you do to help me?” This approach sparked curiosity and engagement, enabling employees to explore AI-driven solutions tailored to their roles.

The Benefits of AI for Genmab Employees

The adoption of ChatGPT Enterprise has been transformative for Genmab employees. Through comprehensive training programs and personalized guidance, employees have learned to embrace innovative ways of thinking and problem-solving. According to Farhat Siddiqui, ChatGPT Product Manager at Genmab, Learning to use ChatGPT has been a transformative journey for our employees. Our comprehensive training programs and personalized guidance have empowered them to embrace innovative ways of thinking and problem-solving.

In fact, a recent survey revealed that ChatGPT Enterprise saves employees an average of 3.5 hours per week, with many employees reporting that they couldn’t imagine performing certain aspects of their jobs without the assistance of ChatGPT.

AI in Research, Workflows, and Translation

One of the most significant benefits of Genmab’s AI Everywhere initiative is the creation of over 100 custom GPTs. These AI models assist in a wide range of tasks, from drafting documents and summarizing scientific literature to performing advanced analytics. GPT-4o, the latest version of OpenAI’s language model, has provided significant enhancements, particularly in interpreting complex documents containing images, text, and numbers. This has revolutionized how Genmab verifies factual references in medical affairs publications, saving both time and costs.

Genmab has developed AI Translator GPT, a state-of-the-art tool that translates complex scientific documents with human-like accuracy. This tool mimics a human translation team, performing roles such as translator, editor, and specialized agent for biological content. Notably, this tool has drastically reduced translation times from weeks to minutes by incorporating a reverse translation process and staging language approach.

Security and Privacy Compliance with OpenAI

As a company dealing with sensitive scientific data, security and privacy compliance were critical factors in Genmab’s decision to partner with OpenAI. Genmab conducted a thorough evaluation of OpenAI’s security and privacy protocols, including a detailed assessment of data handling practices, encryption standards, and compliance with international data protection regulations such as GDPR.

This evaluation, which involved internal and external experts, ensured that OpenAI’s solutions met Genmab’s stringent requirements for data protection. By prioritizing security, Genmab has been able to fully leverage the capabilities of ChatGPT Enterprise without compromising on confidentiality.

Building a Partnership with OpenAI

Rather than working with a standard cloud provider, Genmab chose to partner directly with OpenAI, ensuring close collaboration with AI experts to push the boundaries of AI capabilities. Hisham Hamadeh, Senior Vice President and Global Head of Data Sciences & AI at Genmab, emphasized the importance of this partnership, stating, Our partnership with OpenAI not only highlights Genmab's commitment to innovation, but also aims to unleash every colleague’s inner algorithmic leader to truly unlock large language model’s potential.

This partnership has enabled Genmab to integrate AI into its clinical trial operations, including the creation of clinical study reports, patient safety narratives, and investigational new drug (IND) applications. By continuously improving AI models with clinical data, Genmab is using AI to solve complex problems in drug development.

The Future of AI in Biopharmaceuticals

Genmab’s AI Everywhere initiative is a testament to the company’s commitment to innovation and its belief in the transformative power of AI. As Scott Ogden, Head of Genmab’s AI Lab, explained, Our vision goes beyond just streamlining processes; we're aiming to fundamentally transform how we discover, develop, and deliver treatments to patients.

The advancements in AI at Genmab are a clear indicator that the biopharmaceutical industry is on the cusp of significant change. With more powerful and efficient AI models on the horizon, the industry can expect unprecedented levels of reasoning, understanding, and problem-solving capabilities.

Conclusion

Genmab’s launch of AI Everywhere marks a pivotal moment in the integration of AI into biopharmaceutical research and operations. By adopting ChatGPT Enterprise, developing custom AI models, and partnering directly with OpenAI, Genmab is not only enhancing its internal operations but also reshaping how cutting-edge treatments are discovered and developed. As AI continues to evolve, Genmab’s commitment to innovation ensures it will remain at the forefront of advancements in the industry, ultimately delivering life-changing therapies to patients around the world.

For more information about ChatGPT Enterprise and the partnership with OpenAI, visit OpenAI's official website. Learn more about Genmab’s cutting-edge work in antibody therapies on Genmab’s website.